PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF LY2951742, A CALCITONIN GENE RELATED PEPTIDE ANTIBODY, IN MIGRAINE PATIENTS

被引：0
|
作者：
Kielbasa, W. [1 ]
Quinlan, T. [1 ]
Bell, R. [1 ]
Miller, B. [2 ]
Skljarevski, V. [3 ]
机构：
[1] Eli Lilly & Co, Global PKPD, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Neurosci Tailoring, Indianapolis, IN 46285 USA
[3] Eli Lilly & Co, Med, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2016年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EHMTC-0112
引用
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetic and Pharmacodynamic Modeling of LY2951742, a Calcitonin Gene Related Peptide Antibody, in Migraine Patients
    Kielbasa, William
    Quinlan, Tonya
    Bell, Robert
    Millen, Bradley
    Skljarevski, Vladimir
    NEUROLOGY, 2016, 86
  • [2] Pharmacokinetic and pharmacodynamic modeling of LY2951742, a calcitonin gene related peptide antibody, in migraine patients
    Kielbasa, W.
    Quinlan, T.
    Bell, R.
    Miller, B.
    Skljarevski, V
    HEADACHE, 2016, 56 : 61 - 62
  • [3] Evaluation of treatment-emergent anti-drugantibodies following administration of LY2951742, a calcitonin gene related peptide antibody, to migraine patients
    Miller, B.
    Collins, E. C.
    Hodsdon, M.
    Camporeale, A.
    Nguyen, H.
    Oakes, T.
    Zhang, Q.
    Ferguson, M.
    Skljarevski, V
    Martinez, J. M.
    Johnson, K. W.
    Schacht, A. L.
    Due, M. R.
    Kielbasa, W.
    Yang, J.
    HEADACHE, 2016, 56 : 68 - 69
  • [4] EVALUATION OF TREATMENT-EMERGENT ANTI-DRUG-ANTIBODIES (TE-ADA) FOLLOWING ADMINISTRATION OF LY2951742, A CALCITONIN GENE RELATED PEPTIDE (CGRP) ANTIBODY, TO PATIENTS WITH MIGRAINE
    Miller, B.
    Collins, E.
    Hodsdon, M.
    Camporeale, A.
    Nguyen, H.
    Oakes, T.
    Zhang, Q.
    Ferguson, M.
    Skljarevski, V.
    Martinez, J.
    Johnson, K.
    Schacht, A.
    Due, M.
    William, K.
    Yan, Y. Jyun
    CEPHALALGIA, 2016, 36 : 35 - 36
  • [5] Efficacy of LY2951742 in subgroups of patients with migraine of different frequency
    Skljarevski, V
    Martinez, J. M.
    Oakes, T.
    Ferguson, M.
    Tanaka, Y.
    Due, M. R.
    Schacht, A. L.
    HEADACHE, 2016, 56 : 67 - 67
  • [6] Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model
    Vermeersch, Steve
    Benschop, Robert J.
    Van Hecken, Anne
    Monteith, David
    Wroblewski, Victor J.
    Grayzel, David
    de Hoon, Jan
    Collins, Emily C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 354 (03): : 350 - 357
  • [7] EFFICACY OF LY2951742 IN SUBGROUPS OF PATIENTS WITH MIGRAINE OF DIFFERENT FREQUENCY
    Skljarevski, V.
    Martinez, J.
    Oakes, T.
    Ferguson, M.
    Tanaka, Y.
    Due, M.
    Schacht, A.
    CEPHALALGIA, 2016, 36 : 42 - 43
  • [8] Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
    Dodick, David W.
    Goadsby, Peter J.
    Spierings, Egilius L. H.
    Scherer, Joel C.
    Sweeney, Steven P.
    Grayzel, David S.
    LANCET NEUROLOGY, 2014, 13 (09): : 885 - 892
  • [9] Onset of efficacy of LY2951742 in migraine prevention: post-hoc analysis of phase 2a, randomized, double-blind, placebo-controlled study data of a calcitonin gene-related peptide monoclonal antibody
    Goadsby, P. J.
    Dodick, D.
    Martinez, J.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Skljarevski, V.
    CEPHALALGIA, 2015, 35 : 55 - 55
  • [10] Sustained response outcomes from a phase 2a, randomized, double-blind, placebo-controlled study of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a post-hoc analysis
    Dodick, D. W.
    Goadsby, P. J.
    Skljarevski, V.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Martinez, J.
    CEPHALALGIA, 2015, 35 : 52 - 52
12345